Interview With James Hallifax

Is MindMed (MMED / MMEDF) the next Tesla (TSLA)? It could be. In this video we give the bull case scenario for MindMed, and give a general company overview.

MindMed (MMED) is our favorite psychedelic stock by far, with trials using LSD to treat anxiety and ADHD, as well as their proprietary 18-MC compound to treat addiction.

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

Music: www.bensound.com
► Music Credit: LAKEY INSPIRED
Track Name: “Blue Boi”
Music By: LAKEY INSPIRED @ https://soundcloud.com/lakeyinspired

Original upload HERE – https://www.youtube.com/watch?v=wAukv…
Official “LAKEY INSPIRED” YouTube Channel HERE – https://www.youtube.com/channel/UCOmy…
License for commercial use: Creative Commons Attribution 3.0 Unported “Share Alike” (CC BY-SA 3.0) License.
Full License HERE – https://creativecommons.org/licenses/…

Music promoted by NCM https://goo.gl/fh3rEJ

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Links from studies and websites :
https://www.cdc.gov/nchs/pressroom/podcasts/20190911/20190911.htm?fbclid=IwAR3_UBSk2yv4lwOld0su1YpnJHsjPA4x5XK-X2pO5LMz1AeXiojkswcDV8Y#:~:text=Anestimated69029peopledied,wereduetoheroin

https://www.hhs.gov/opioids/about-the-epidemic/index.html?fbclid=IwAR0df0UXoVhfWf03RQNkP5OMInM5Nyxz6j68V5GXr5lv0lDUuRL_R-UL4ZA

https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/opioid-addiction?fbclid=IwAR31PQiu49359xjhzD4sTgcicRQLGh-l95y2DuFihHPdql87eHTDnYsTELw

https://preprod.drugfree.org/article/relapse-overdose/?fbclid=IwAR1YSZEIUDCiYDeBIYCk1WhEA_NJCrjyyz56zteyrbGKhDYQtsu2X1fDVOM

https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery?fbclid=IwAR2_c4gVhURANeU5pCc0k97Ba4ML-kYZIGOZvGfqpHmo8o4jdxZp0SEHyQQ

https://maps.org/research-archive/presentations/Brown_GITA_Vancouver_Oct2012_iboga_comm_rev.pdf

https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1310218?fbclid=IwAR0OBK0eFJ64-v7gu1yE1TnyUIK1XhSDJvd_XLxhZaRtC4bWF8MfD0ine3M

https://www.healio.com/news/primary-care/20191205/ibogaine-treatment-for-opioid-use-disorder-what-you-need-to-know?fbclid=IwAR39o1sonUGLHsMGwH3pzbm3aAkU98P15CFNYaQX0r3VNQtJdSy3pazvRJM#

https://mindmed.co/psychedelic-inspired/?fbclid=IwAR1EK84fYX4WrObq45LkQfkZiW3ZtUYNsVZ4Y9q_wMHqas7y8IwoJmFyTBs#scroll_section-1

https://www.globenewswire.com/news-release/2020/02/20/1988216/0/en/Drug-Addiction-Treatment-Market-To-Reach-USD-31-17-Billion-By-2027-Reports-And-Data.html?fbclid=IwAR2ZeDBuW69x1DkczkxVRmadUBTpwu1Dilur64LkqBISH1Dqu8FC3EgFzmU

https://adaa.org/about-adaa/press-room/facts-statistics?fbclid=IwAR2YlG6rTd0jdUP3XIkm0t-_-QRYDyWDlVGh_sF6CZkayVEyGUZZpGcplwE#:~:text=Anxietydisordersarethemost,ofthosesufferingreceivetreatment

https://adaa.org/finding-help/treatment/medication?fbclid=IwAR10tRsqwdRMx-PqpKA9yx5BPGvNcVJRugkw3L6tq7DrDIO4gVdNwb6BGJ4

https://www.newswire.ca/news-releases/mindmed-receives-approval-of-protocol-design-to-evaluate-microdoses-of-lsd-for-adult-adhd-in-phase-2a-clinical-trial-from-swiss-and-dutch-health-authorities-897700369.html?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng

https://maps.org/research-archive/lsd/Gasser-2014-JMND-4March14.pdf

https://www.smartpatients.com/trials/NCT03153579?fbclid=IwAR0df0UXoVhfWf03RQNkP5OMInM5Nyxz6j68V5GXr5lv0lDUuRL_R-UL4ZA

https://www.marketwatch.com/press-release/global-anxiety-disorders-and-depression-treatment-market-2020-research-report-with-consumption-revenue-opportunities-market-share-and-growth-rate-covid-19-impact-and-forecast-to-2026-absolute-reports-2020-11-06?fbclid=IwAR1jEtR6h9mTPla8OzW5RiIW2ecf_HnrT7of42bU4mO5dsfpxxuCAFv-7bE

https://www.additudemag.com/statistics-of-adhd/?fbclid=IwAR1mQaSVujUayYXwzCQRryiCZzM4gckjKAbg5O9H5BwCJIUbrXypOlgU4qM#:~:text=About6.1millionchildrenin,ControlandPrevention(CDC)

https://www.additudemag.com/adhd-medication-for-adults-and-children/?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng

https://www.floridarehab.com/drugs/meth/related/meth-vs-adderall/?fbclid=IwAR0WbOJtUIMcW4sPsQ7TUR-ulrPC9rwa1b2_KxHw_lFJBk_ygesCtsQJqDs

https://www.drugwatch.com/adderall/side-effects/?fbclid=IwAR3_UBSk2yv4lwOld0su1YpnJHsjPA4x5XK-X2pO5LMz1AeXiojkswcDV8Y

https://drug-dev.com/adhd-treatment-market-value-to-reach-9-9-billion/?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng

https://mindmed.co/team/

#MindMed #MMED #Mindmedstock #Tesla #TSLA #PsychedelicStocks #ThePsychedelicInvestor

Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG esketamine study results, new 5MEO-DMT tests and Updates on the decriminalization efforts in California and Texas.

In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

1. We’ll cover some interesting and maybe disappoint results coming from a study designed to determine whether esketamine can treat depression and their implications on some companies such as Numinus Wellness (NUMI), Field Trip Health ( FTRP) and Johnsons & Johnson (JNJ)
2. Study looking at the creativity benefits of taking psilocybin
3. Compass Pathways (CMPS) has amazing new price targets
4. First ever clinical trial testing the safety profile of a compound called 5MEO – DMT
5. A couple of updates on decriminalization efforts

Timestapms:

0:00 – Intro
1:33 – Likelihood of Adverse events from Nasal Esketamine : Implications for Numinus, JNJ and Fieldtrip Health
6:07 – Psilocybin’s effects on creativity in a new placebo-controlled neuroimaging and it’s effects on MindMed (MMED/MMEDF), Compass Pathways (CMPS), Mydecine (MYCO) , Numinus ( NUMI)
11:25 – Researchers to team up to produce the first ever 5-meo-DMT Psychedelic Training Program
12:28 – California bill To Legalize Possession of Psychedelics Clears Second Senate Committee
14:26 – Rick Perry supports the Texas Capital to study psychedelic drugs from PTSD in veterans.

I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#PsychedelicStocks ​#Numi #Mindmed

GUYS. IT HAPPENED. Cathie Wood and ARK Invest have invested in a Psychedelic Stock! Specifically, ARKG, or the ARK Genomic Revolution ETF have purchased atai Life Sciences (Nasdaq: atai)!

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@psycbiz
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Last year, the Psychedelic Investor and the Reddit Page “ShroomStocks” managed to get the question of “would you ever invest in Psychedelic Stocks” asked to Cathie Wood of ARK Invest, and her answer was a dismissive NO. She said that ARK did not invest in binary stocks, though Kevin O’Leary, who was on the same panel disagreed.

Well, it seems that time (and maybe Kevin O’Leary) have changed her mind. On Wednesday, February 9th, it was revealed that the Ark Genomic Revolution ETF, ticker symbol ARKG, had purchased 83,278 shares of ATAI.

And while this only represents 0.01% of that fund’s total holdings, it does represent a big moment for the entire psychedelics industry. For better or worse, Cathie Wood has a huge voice among investors who like growth stocks, and next-generation technology stocks, which psychedelic stocks definitely represent.

This will likely put more focus, not only on atai, but the entire psychedelics sector. I would not be surprised if companies such as MindMed (MMEDF) and Cybin (CYBN) also benefit from this. Perhaps, in the future, Ark will also buy these companies.

Hopefully, this is but an opening position, and ARKG continues to buy psychedelic stocks such as atai and MindMed. Ideally, I would also like to see the flagship ETF, ARKK, also invest in psychedelic Stocks.

#CathieWood #ARKG #PsychedelicStocks